Use of the French national health insurance information system for research in the field of mental health: Systematic review and perspectives.
French health insurance database
Système national des données de santé
cohort
electronic claims databases
mental health research
pharmacoepidemiology
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
05
05
2021
received:
22
03
2021
accepted:
12
05
2021
pubmed:
18
5
2021
medline:
18
1
2022
entrez:
17
5
2021
Statut:
ppublish
Résumé
This systematic review registered in PROSPERO (CRD42021225296) aimed to describe the use of the French national health insurance information system, which covers the entire French population (67 million inhabitants), for research in the field of mental health. Three electronic databases and a journal hand-search identified 15 265 articles from January 1, 2003 (year of creation of the database) to October 31, 2020. Studies of any design were eligible for inclusion provided that they (i) made use of at least one component of the French health insurance database and (ii) focused on a topic in near and far connection with the field of mental health in France. Database used, design and methods, study period, population, key findings, and type of use for medical research were described. A total of 152 studies were included in the review analysis. There was an increase in the number of published articles over time throughout the studied period. Studies focusing on adults (n = 139) largely outnumbered those focusing on children and adolescents (n = 11). Pharmacoepidemiological studies were by far the most frequent (n = 123), followed by methodological studies (n = 23), epidemiological studies (n = 17), and health economics studies (n = 3). The most studied psychotropic drugs were antidepressants (n = 27), anxiolytics (n = 27), and opioids (n = 25) while fewer studies focused on methylphenidate (n = 6) and on mood stabilizers (n = 5). Few studies specifically focused on psychiatric disorders, mainly depression (n = 4), suicide (n = 4), and psychotic disorders (n = 3). This systematic review highlighted a relatively poor exploitation of the Système national des données de santé database in the field of psychiatric research with regard to the great possibilities it offers, with a clear lag in certain fields such as epidemiological or health economics studies and in specific populations, in particular children and adolescents.
Substances chimiques
Psychotropic Drugs
0
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
16-34Informations de copyright
© 2021 Société Française de Pharmacologie et de Thérapeutique.
Références
Mental Health Burden - World Health Organization. https://www.who.int/health-topics/mental-health#tab=tab_2. Accessed April 28, 2021.
Trautmann S, Rehm J, Wittchen H-U. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep. 2016;17:1245-1249.
Razzouk D. Burden and Indirect Costs of Mental Disorders. In: Razzouk D, ed. Mental Health Economics: The Costs and Benefits of Psychiatric Care. Berlin: Springer International Publishing; 2017:381-391.
Hazo J-B, Gervaix J, Gandré C, Brunn M, Leboyer M, Chevreul K. European Union investment and countries’ involvement in mental health research between 2007 and 2013. Acta Psychiatr Scand. 2016;134:138-149.
Hazo J-B, Brunn M, Wykes T, et al. European mental health research resources: Picture and recommendations of the ROAMER project. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2019;29:179-194.
Hazo J-B, Gandré C, Leboyer M, et al. National funding for mental health research in Finland, France, Spain and the United Kingdom. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2017;27:892-899.
Patel V. Mental health research funding: too little, too inequitable, too skewed. Lancet Psychiatry. 2021;8:171-172.
Manwell LA, Barbic SP, Roberts K, et al. What is mental health? Evidence towards a new definition from a mixed methods multidisciplinary international survey. BMJ Open. 2015;5:e007079.
Galderisi S, Heinz A, Kastrup M, Beezhold J, Sartorius N. Toward a new definition of mental health. World Psychiatry. 2015;14:231-233.
Falissard B, Monégat M, Harper G. Psychiatry, mental health, mental disability: time for some necessary clarifications. Eur Child Adolesc Psychiatry. 2017;26:1151-1154.
World Health Organization. Promoting Mental Health: Concepts, Emerging Evidence, Practice (Summary Report). Geneva: World Health Organization; 2004.
Forsman AK, Wahlbeck K, Aarø LE, et al. Research priorities for public mental health in Europe: recommendations of the ROAMER project. Eur J Public Health. 2015;25:249-254.
Wykes T, Haro JM, Belli SR, et al. Mental health research priorities for Europe. Lancet Psychiatry. 2015;2:1036-1042.
Leboyer M. Études de cohortes en psychiatrie : expériences européennes. 2012. http://www.fondation-fondamental.org/files/Etudes-de-cohortes-en-psychiatrie. Accessed August 11, 2018.
Gavrielov-Yusim N, Friger M. Use of administrative medical databases in population-based research. J Epidemiol Community Health. 2014;68:283-287.
Morrato EH, Elias M, Gericke CA. Using population-based routine data for evidence-based health policy decisions: lessons from three examples of setting and evaluating national health policy in Australia, the UK and the USA. J Public Health Oxf Engl. 2007;29:463-471.
Kimura T, Matsushita Y, Yang Y-HK, Choi N-K, Park B-J. Pharmacovigilance systems and databases in Korea, Japan, and Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:1237-1245.
Kreis K, Neubauer S, Klora M, Lange A, Zeidler J. Status and perspectives of claims data analyses in Germany-A systematic review. Health Policy Amst Neth. 2016;120:213-226.
Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149-S167.
Montastruc J-L, Benevent J, Montastruc F, et al. What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie. 2019;74:169-174.
AsPEN collaborators, Andersen M, Bergman U, et al. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia. Pharmacoepidemiol Drug Saf. 2013;22:700-704.
Charlton RA, Neville AJ, Jordan S, et al. Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf. 2014;23:586-594.
Bazelier MT, Eriksson I, de Vries F, et al. Data management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: a systematic literature review. Pharmacoepidemiol Drug Saf. 2015;24:897-905.
Munk-Jørgensen P, Okkels N, Golberg D, Ruggeri M, Thornicroft G. Fifty years’ development and future perspectives of psychiatric register research. Acta Psychiatr Scand. 2014;130:87-98.
Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44:827-836.
Wettermark B, Zoëga H, Furu K, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research-a literature review. Pharmacoepidemiol Drug Saf. 2013;22:691-699.
Conte C, Vaysse C, Bosco P, et al. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology. Therapies. 2019;74:279-288.
Latry P, Molimard M, Bégaud B, Martin-Latry K. How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database. Eur J Clin Pharmacol. 2010;66:743-748.
Martin-Latry K, Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can!. Pharmacoepidemiol Drug Saf. 2010;19:256-265.
Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc J-L, Sailler L. French health insurance databases: What interest for medical research? Rev Med Interne. 2015;36:411-417.
Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol. 2016;30:616-624.
Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954-962.
Nay O, Béjean S, Benamouzig D, Bergeron H, Castel P, Ventelou B. Achieving universal health coverage in France: policy reforms and the challenge of inequalities. Lancet Lond Engl. 2016;387:2236-2249.
Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58:286-290.
Loi no 2016-41 du 26 janvier 2016 de modernisation de notre système de santé. JORF 2016;0022. https://www.legifrance.gouv.fr/loda/id/JORFTEXT000031912641/. Accessed November 20, 2020.
Richaud-Eyraud E, Ellini A, Clément M-C, Menu A, Dubois J. Qualité du codage des diagnostics et motifs de prise en charge (principal et associés) dans le recueil d’informations médicalisé en psychiatrie (RIM-P) en 2015 et 2016. France. Rev DÉpidémiologie Santé Publique. 2019;67:337-344.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Rousselot N, Pariente A, Mansiaux Y, Victorri-Vigneau C. Impact of secured prescription implementation for zolpidem on hypnotics use in France: A time-series analysis on national data. Ann Fam Med. 2020;18:345-348.
Damase-Michel C, Lacroix I, Hurault-Delarue C, Beau A-B, Montastruc J-L. les partenaires d’EFEMERIS. [Drug in pregnancy: studies in the French database EFEMERIS]. Therapie. 2014;69:91-100.
Montastruc F, Bénard-Laribière A, Noize P, et al. Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol. 2018;74:619-626.
Kovess-Masfety V, Balusson F, Leray E, Husky M, Scailteux L-M. Prescription patterns of first- and second-generation antipsychotic drugs in the French population. Fundam Clin Pharmacol. 2020;34:603-611.
Revet A, Montastruc F, Raynaud J-P, Baricault B, Montastruc J-L, Lapeyre-Mestre M. Trends and patterns of antidepressant use in French Children and Adolescents From 2009 to 2016: a population-based study in the French Health Insurance Database. J Clin Psychopharmacol. 2018;38:327-335.
Verdoux H, Cougnard A, Auleley G-R, et al. Antipsychotic use patterns in persons initially treated with mood stabilizers: a naturalistic study. Pharmacopsychiatry. 2010;43:17-23.
Etchepare F, Sanglier T, André M, Verdoux H, Tournier M. Antidepressant treatment patterns in younger and older adults from the general population in a real-life setting. Int J Geriatr Psychiatry. 2014;29:928-935.
Hurault-Delarue C, Lacroix I, Benard-Laribiere A, Montastrue J-L, Pariente A, Damase-Michel C. Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort. Eur Arch Psychiatry Clin Neurosci. 2019;269:841-849.
Ponté C, Lepelley M, Boucherie Q, et al. Doctor shopping of opioid analgesics relative to benzodiazepines: a pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug Alcohol Depend. 2018;187:88-94.
Soeiro T, Frauger É, Pradel V, Micallef J. Doctor shopping for methylphenidate as a proxy for misuse and potential abuse in the 67 million inhabitants in France. Fundam Clin Pharmacol. 2020.
Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85:1260-1269.
Jouanjus E, Pourcel L, Saivin S, Molinier L, Lapeyre-Mestre M. Use of multiple sources and capture-recapture method to estimate the frequency of hospitalizations related to drug abuse. Pharmacoepidemiol Drug Saf. 2012;21:733-741.
Victorri-Vigneau C, Feuillet F, Wainstein L, et al. Pharmacoepidemiological characterisation of zolpidem and zopiclone usage. Eur J Clin Pharmacol. 2013;69:1965-1972.
Palmaro A, Dupouy J, Lapeyre-Mestre M. Benzodiazepines and risk of death: results from two large cohort studies in France and UK. Eur Neuropsychopharmacol. 2015;25:1566-1577.
Tournier M, Neumann A, Pambrun E, et al. Conventional mood stabilizers and/or second-generation antipsychotic drugs in bipolar disorders: a population-based comparison of risk of treatment failure. J Affect Disord. 2019;257:412-420.
Diène E, Geoffroy-Perez B, Cohidon C, et al. Psychotropic drug use in a cohort of workers 4 years after an industrial disaster in France. J Trauma Stress. 2014;27:430-437.
Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V. Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings. Eur Neuropsychopharmacol. 2014;24:95-104.
Bosco-Levy P, Grelaud A, Blin P, et al. Treatment resistant depression incidence and prevalence using the French nationwide claims database. Pharmacoepidemiol Drug Safety. 2021;30(2):169-177.
Fond G, Salas S, Pauly V, et al. End-of-life care among patients with schizophrenia and cancer: a population-based cohort study from the French national hospital database. Lancet Public Health. 2019;4:e583-e591.
Gandre C, Gervaix J, Thillard J, Mace J-M, Roelandt J-L, Chevreul K. Involuntary Psychiatric Admissions and Development of Psychiatric Services as an Alternative to Full-Time Hospitalization in France. Psychiatr Serv. 2017;68:923-930.
Alkhafaji AA, Trinquart L, Baron G, Desvarieux M, Ravaud P. Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants. BMC Med. 2012;10:142.
Tournier M, Crott R, Gaudron Y, Verdoux H. Economic impact of antidepressant treatment duration in naturalistic conditions. Acta Psychiatr Scand. 2013;127:365-372.
Tournier M, Bégaud B, Cougnard A, et al. Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers. Br J Clin Pharmacol. 2012;74:189-196.
Chan Chee C, Chin F, Ha C, Beltzer N, Bonaldi C. Use of medical administrative data for the surveillance of psychotic disorders in France. BMC Psychiatry. 2017;17:386.
Quantin C, Benzenine E, Hägi M, et al. Estimation of national colorectal-cancer incidence using claims databases. J Cancer Epidemiol. 2012;2012:298369.
Bannay A, Chaignot C, Blotière P-O, et al. The best use of the charlson comorbidity index with electronic health care database to predict mortality. Med Care. 2016;54:188-194.
Filipovic-Pierucci A, Samson S, Fagot J-P, Fagot-Campagna A. Estimating the prevalence of depression associated with healthcare use in France using administrative databases. BMC Psychiatry. 2017;17:1.
Chan Chee C, Paget L-M. The psychiatric hospital discharge database (RIM-P): An essential tool for the surveillance of hospitalization after a suicide attempt. Rev Epidemiol Sante Publique. 2017;65:349-359.
Verdoux H, Pambrun E, Tournier M, Cortaredona S, Verger P. Multi-trajectories of antidepressant and antipsychotic use: a 11-year naturalistic study in a community-based sample. Acta Psychiatr Scand. 2019;139:536-547.
Palmaro A, Boucherie Q, Dupouy J, Micallef J, Lapeyre-Mestre M. Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies? Pharmacoepidemiol Drug Saf. 2017;26:544-553.
Kaguelidou F, Sommet A, Lapeyre-Mestre M. Use of French healthcare insurance databases in pediatric pharmacoepidemiology. Therapie. 2018;73:127-133.
Suissa S, Henry D, Caetano P, et al. CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med Peer-Rev Indep Open-Access J. 2012;6:e134-140.
Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration’s Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):1-8.
Allebeck P. The use of population based registers in psychiatric research. Acta Psychiatr Scand. 2009;120:386-391.
Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490.
Munk-Jørgensen P, Kastrup M, Mortensen PB. The Danish psychiatric register as a tool in epidemiology. Acta Psychiatr Scand Suppl. 1993;370:27-32.
Munk-Jørgensen P, Østergaard SD. Register-based studies of mental disorders. Scand J Public Health. 2011;39(7 Suppl):170-174.
Byrne N, Regan C, Howard L. Administrative registers in psychiatric research: a systematic review of validity studies. Acta Psychiatr Scand. 2005;112:409-414.
Lauritsen MB, Jørgensen M, Madsen KM, et al. Validity of childhood autism in the Danish Psychiatric Central Register: findings from a cohort sample born 1990-1999. J Autism Dev Disord. 2010;40:139-148.
Uggerby P, Østergaard SD, Røge R, Correll CU, Nielsen J. The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. Dan Med J. 2013;60:A4578.
Vernal DL, Stenstrøm AD, Staal N, et al. Validation study of the early onset schizophrenia diagnosis in the Danish Psychiatric Central Research Register. Eur Child Adolesc Psychiatry. 2018;27:965-975.
Nissen J, Powell S, Koch SV, et al. Diagnostic validity of early-onset obsessive-compulsive disorder in the Danish Psychiatric Central Register: findings from a cohort sample. BMJ Open. 2017;7:e017172.
Frederiksen LH, Bilenberg N, Andersen L, et al. The validity of child and adolescent depression diagnoses in the Danish psychiatric central research register. Acta Psychiatr Scand. 2021;143:264-274.
Svensson E, Lash TL, Resick PA, Hansen JG, Gradus JL. Validity of reaction to severe stress and adjustment disorder diagnoses in the Danish Psychiatric Central Research Registry. Clin Epidemiol. 2015;7:235-242.
Coloma PM, Schuemie MJ, Trifirò G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20:1-11.
Goldberg M, Carton M, Doussin A, et al. The REDSIAM network. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S144-S148.
Quantin C, Collin C, Frérot M, et al. Study of algorithms to identify schizophrenia in the SNIIRAM database conducted by the REDSIAM network. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S226-S235.
Hálfdánarson Ó, Zoëga H, Aagaard L, et al. International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2017;27:1064-1076.
Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136:37-51.
ENCePP Home Page. http://www.encepp.eu/standards_and_guidances/methodologicalGuide.shtml. Accessed February 18, 2021.
Boyd PA, Haeusler M, Barisic I, Loane M, Garne E, Dolk H. Paper 1: The EUROCAT network-organization and processes. Birt Defects Res A Clin Mol Teratol. 2011;91(Suppl 1):S2-15.
Murray ML, Insuk S, Banaschewski T, et al. An inventory of European data sources for the long-term safety evaluation of methylphenidate. Eur Child Adolesc Psychiatry. 2013;22:605-618.
Verger P, Cortaredona S, Tournier M, et al. Psychotropic drug dispensing in people with and without cancer in France. J Cancer Surviv. 2017;11:92-101.
Conte C, Rueter M, Laurent G, Bourrel R, Lapeyre-Mestre M, Despas F. Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin’s lymphoma: a cohort study of the French national health insurance database. Support Care Cancer. 2016;24:4791-4799.
Billioti de Gage S, Collin C, Le-Tri T, et al. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. CNS Drugs. 2018;32:673-684.
Chenaf C, Kaboré J-L, Delorme J, et al. Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality. Eur J Pain Lond Engl. 2019;23:124-134.
Davis KAS, Farooq S, Hayes JF, et al.Pharmacoepidemiology research: delivering evidence about drug safety and effectiveness in mental health. Lancet Psychiatry. 2020;7:363-370.